Evidence map›Paper›PMID 22644214›Full record

ArticleThe journal of headache and pain2012

Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS).

L M Bloudek, M Stokes, D C Buse, T K Wilcox, R B Lipton, P J Goadsby, S F Varon, A M Blumenfeld, Z Katsarava, J Pascual and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of headache and pain, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 19 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 19 syntheses or guidelines pooled it, 339 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Zolmitriptan for acute migraine attacks in adults.The Cochrane database of systematic reviews · 2014
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Guideline
  20. Trial

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 6 countries.

L M BloudekAllergan Inc., 2525 Dupont Drive, Irvine, CA, 92612, USA. Bloudek_Lisa@Allergan.com
M Stokes
D C Buse
T K Wilcox
R B Lipton
P J Goadsby
S F Varon
A M Blumenfeld
Z Katsarava
J Pascual
M Lanteri-Minet
P Cortelli
P Martelletti
Albert Einstein College of Medicine · USAllergan (Ireland) · IEAllergan (United States) · USFreedom to Live · USHospital Universitario Central de Asturias · ESInstitut de Chimie de Nice · FRSapienza University of Rome · ITUniversity of Bologna · ITUniversity of California, San Francisco · USUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine is a disabling neurological disease that affects 14.7 % of Europeans. Studies evaluating the economic impact of migraine are complex to conduct adequately and with time become outdated as healthcare systems evolve. This study sought to quantify and compare direct medical costs of chronic migraine (CM) and episodic migraine (EM) in five European countries. Cross-sectional data collected via a web-based survey were screened for migraine and classified as CM (≥15 headache days/month) or EM (<15 headache days/month), and included sociodemographics, resource use data and medication use. Unit cost data, gathered using publicly available sources, were analyzed for each type of service, stratified by migraine status. Univariate and multivariate log-normal regression models were used to examine the relationship between various factors and their impact on total healthcare costs. This economic analysis included data from respondents with migraine in the UK, France, Germany, Italy, and Spain. CM participants had higher level of disability and more prevalent psychiatric disorders compared to EM. CM participants had more provider visits, emergency department/hospital visits, and diagnostic tests; the medical costs were three times higher for CM than EM. Per patient annual costs were highest in the UK and Spain and lower in France and Germany. CM was associated with higher medical resource use and total costs compared to EM in all study countries, suggesting that treatments that reduce headache frequency could decrease the clinical and economic burden of migraine in Europe. Comparing patterns of care and outcomes among countries may facilitate the development of more cost-effective care, and bring greater recognition to patients affected by migraine.

Indexed as

Health Care CostsCross-Sectional StudiesEuropeFemaleHealth SurveysHumansMaleMigraine DisordersPersons with Disabilities

Identifiers

PMID22644214
PMCPMC3381065
OpenAlexW2094473459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.